ADMA
ADMA Biologics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website admabiologics.com
- Employees(FY) 617
- ISIN US0008991046
Performance
-2.44%
1W
-15.08%
1M
+4.52%
3M
+83.48%
6M
+325.0%
YTD
+419.19%
1Y
Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Technical Analysis of ADMA 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-04 09:55
- 2024-12-03 19:00
ADMA: Lowering target price to $26.00(Argus Research)
- 2024-12-02 14:16
- 2024-11-27 09:40
- 2024-11-26 19:00
ADMA: Raising target price to $28.00(Argus Research)
- 2024-11-26 09:51
Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge(Investor's Business Daily)
- 2024-11-18 09:55
- 2024-11-15 09:30
- 2024-11-15 06:16
- 2024-11-12 19:00
ADMA: Raising target price to $26.00(Argus Research)
- 2024-11-12 09:15
- 2024-11-11 14:06
Vericel Stock Sees RS Rating Shoot Higher(Investor's Business Daily)
- 2024-11-11 09:40
- 2024-11-09 08:42
- 2024-11-08 12:19
Q3 2024 ADMA Biologics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-08 02:28
- 2024-11-07 19:20
- 2024-11-07 18:17
Adma Biologics: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-07 17:37
- 2024-11-07 16:05
- 2024-11-07 09:10
3 High Growth Tech Stocks Leading The US Market(Simply Wall St.)
- 2024-11-06 07:08
- 2024-11-05 19:00
ADMA: Lowering target price to $21.00(Argus Research)
- 2024-11-05 14:02
- 2024-11-04 14:34
- 2024-11-04 09:05
3 US Stocks That May Be Trading Below Estimated Value(Simply Wall St.)
- 2024-11-01 16:08
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle(Investor's Business Daily)
- 2024-10-30 09:30
- 2024-10-29 17:50
- 2024-10-29 16:10
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.